🌐 EnglishEN

AI Cure is a research tool showing open data. Not medical advice. Discuss with your doctor. Terms

← Trials
🧪

Hypofractionated Radiotherapy With Concomitant Tumor Bed Boost for Breast Cancer

Recruitingn/aAges 20 Years - 85 YearsFemaleNational Taiwan University Hospital
NCT06984250 on ClinicalTrials.gov ↗
💬

In plain words

What the trial is, and whether it could suit you

Hypofractionated breast radiotherapy with concomitant tumor bed boost for early breast cancer or ductal breast carcinoma in situ after partial mastectomy

Sign in to get the eligibility rules as simple questions to take to your doctor.

Sign in
📋 Eligibility rules (as published)
Inclusion Criteria: * Female patients with histologically confirmed early-stage breast cancer (T1-2 and N0-1) or ductal carcinoma in situ (DCIS). * Patients undergoing breast-conserving surgery * Age ≥ 20 years * Karnofsky Performance Status (KPS) ≥70% * Life expectancy ≥ 5 years * Adequate renal and hepatic function Exclusion Criteria: * Pregnant patients * Patients requiring re-irradiation of the thoracic region
💊

What it tests

  • Hypofractionated Radiation Therapy
📍

Where

2 sites
National Taiwan University Hospital
Taipei, Taiwan
National Taiwan University Hospital Yunlin Branch
Taipei, Taiwan
🤝 Taking part is your choice, and you can leave at any time. Only the trial team can confirm you are eligible — always decide together with your own doctor.
🛡️

AI Cure shows public evidence (Open Targets, ClinicalTrials.gov, PubMed, openFDA, DepMap, AlphaFold) with its source, and AI summaries that cite it — not medical advice and not a cure. Treatment decisions belong with your doctor. Research ideas are shared only with approved researchers and labs, who can test them. In an emergency call your local emergency number (112 in India and Europe, 911 in the US). AI Cure Terms of Use · Privacy